News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Genetown
Biogen Idec, Inc. (Massachusetts) to Present at the Morgan Stanley Global Healthcare Conference
August 30, 2013
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Morgan Stanley Global Healthcare Conference. The webcast will be live on Monday, September 9, 2013 at 3:15p.m. ET. To access the live webcast, please visit Biogen Idec’s Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
Help employers find you! Check out all the
jobs
and
post your resume
.
Twitter
LinkedIn
Facebook
Email
Print
Events
Biogen
MORE ON THIS TOPIC
Immunology and inflammation
Novartis Presents New Data From Potential First Targeted Sjögren’s Treatment
October 29, 2025
·
3 min read
·
Heather McKenzie
Cell and Gene Therapy
Meeting on the Mesa Arrives Amid Mixed Signals for Cell and Gene Therapy
October 6, 2025
·
5 min read
·
Ben Hargreaves
Multiple sclerosis
Beyond BTK Inhibitors: Next Gen MS Treatments Could Transcend Symptom Management
October 6, 2025
·
5 min read
·
Ben Hargreaves
CDC
Republicans Ratchet Up Pressure as Monarez Levels Damning Allegations Against Kennedy
September 17, 2025
·
4 min read
·
Heather McKenzie